Emicizumab

ApprovedActive

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Severe Hemophilia A

Conditions

Severe Hemophilia A, Moderate Hemophilia A

Trial Timeline

Jun 20, 2022 → May 21, 2027

NCT ID

NCT05181618

About Emicizumab

Emicizumab is a approved stage product being developed by Roche for Severe Hemophilia A. The current trial status is active. This product is registered under clinical trial identifier NCT05181618. Target conditions include Severe Hemophilia A, Moderate Hemophilia A.

What happened to similar drugs?

20 of 20 similar drugs in Severe Hemophilia A were approved

Approved (20) Terminated (6) Active (0)

✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved

✅tacrolimusAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅CefiderocolShionogiApproved

✅Donepezil HClEisaiApproved

✅Donepezil Hydrochloride (Aricept)EisaiApproved

✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05181618	Approved	Active	Jun 20, 2022	May 21, 2027	Severe Hemophilia A
NCT04431726	Phase 3	Active	Feb 4, 2021	May 18, 2030	Severe Hemophilia A
NCT04158648	Phase 3	Completed	Feb 10, 2020	Dec 19, 2025	Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor
NCT03315455	Phase 3	Completed	Apr 26, 2018	Aug 29, 2025	Hemophilia A
NCT03380780	Phase 1	Completed	Mar 12, 2018	Sep 18, 2018	Healthy Volunteers
NCT03191799	Phase 3	Completed	Sep 5, 2017	Nov 19, 2020	Hemophilia A

Competing Products

20 competing products in Severe Hemophilia A

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	44
Drotrecogin alfa (activated)	Eli Lilly	Phase 2	35
CT-P13 SC Auto-Injector + Placebo Auto-Injector	Celltrion	Phase 3	44
CT-P17 + EU-approved Humira	Celltrion	Phase 3	40
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	47
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	44
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	47
CS-3150	Daiichi Sankyo	Phase 3	40
tacrolimus	Astellas Pharma	Approved	43
enzalutamide	Astellas Pharma	Phase 1	29
Isavuconazonium Injection [Cresemba] + Placebo	Astellas Pharma	Phase 3	32
Alefacept	Astellas Pharma	Approved	43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)	Sun Pharmaceutical	Phase 2	35
Tildrakizumab 100 mg + Placebo	Sun Pharmaceutical	Phase 3	44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo	Sun Pharmaceutical	Phase 2/3	42
Cefiderocol	Shionogi	Approved	50
eritoran tetrasodium + Placebo	Eisai	Phase 3	40
Donepezil HCl	Eisai	Approved	43
Donepezil Hydrochloride (Aricept)	Eisai	Approved	35
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40